1. Resurgence of Bordetella pertussis , including one macrolide-resistant isolate, France, 2024.
- Author
-
Rodrigues C, Bouchez V, Soares A, Trombert-Paolantoni S, Aït El Belghiti F, Cohen JF, Armatys N, Landier A, Blanchot T, Hervo M, Toubiana J, and Brisse S
- Subjects
- Humans, France epidemiology, Drug Resistance, Bacterial, Microbial Sensitivity Tests, Bacterial Outer Membrane Proteins genetics, Whole Genome Sequencing, Virulence Factors, Bordetella genetics, Genotype, Adult, Child, Incidence, Child, Preschool, Bordetella pertussis genetics, Bordetella pertussis isolation & purification, Bordetella pertussis drug effects, Macrolides pharmacology, Whooping Cough epidemiology, Whooping Cough microbiology, Anti-Bacterial Agents pharmacology
- Abstract
As other European countries, France is experiencing a resurgence of pertussis in 2024. Between 1 January and 31 May 2024, 5,616 (24.9%) positive Bordetella pertussis qPCR tests were identified, following a 3-year period of almost null incidence. Of 67 cultured and whole genome sequenced B. pertussis isolates, 66 produced pertactin and 56 produced FIM2, in contrast to pre-COVID-19 years. One isolate of genotype Bp-AgST4 was resistant to macrolides. Pertussis resurgence may favour isolates that produce FIM2 and pertactin.
- Published
- 2024
- Full Text
- View/download PDF